Literature DB >> 15918189

Viral and host causes of fatty liver in chronic hepatitis B.

Emin Altlparmak1, Seyfettin Koklu, Mesut Yalinkilic, Osman Yuksel, Bahattin Cicek, Ertugrul Kayacetin, Tulin Sahin.   

Abstract

AIM: To investigate the viral and host causes of fatty liver in chronic hepatitis B patients and the role of fat deposits in liver damage.
METHODS: A total of 164 patients (113 males and 51 females, average age 35+/-11.3 years, and range 10-62 years) with previously untreated chronic hepatitis B were included in the study. The patients were divided into two groups depending on the result of liver biopsy: group without steatosis (100 patients with <5% hepatosteatosis) and group with steatosis (64 patients with >5% hepatosteatosis). The groups were compared in terms of gender, body mass index (BMI), liver enzymes (ALT, AST, ALP, GGT), cholesterol, triglyceride, HBeAg, viral load, and histological findings. In the group with steatosis, the patients were subdivided depending on the degree of steatosis into mild group (45 patients with 5-24% steatosis), and severe group (19 patients with >25% steatosis).
RESULTS: In the group of chronic hepatitis B with steatosis, the mean age, BMI, cholesterol, and triglyceride levels were significantly higher than those in the group without steatosis (P<0.05). Steatosis was found in 53 (46.9%) of male patients and 11 (22%) of female patients (P<0.05). No significant difference was found in the positivity of ALT, AST, ALP, GGT, HBeAg, viral load, histological activity index (HAI) and stage between the two groups (P>0.05). In the group with severe steatosis, the BMI was significantly higher than that in the group with mild steatosis (P<0.05). No significant difference was found in the other parameters between the groups (P>0.05).
CONCLUSION: Steatosis in chronic hepatitis B appears to be a result of metabolic factors of the host rather than the effect of viruses. Steatosis is unrelated to the HAI and degree of fibrosis, which are considered as the histological indicators of liver damage.

Entities:  

Mesh:

Year:  2005        PMID: 15918189      PMCID: PMC4305839          DOI: 10.3748/wjg.v11.i20.3056

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  A renal allograft recipient with viral-burden, steatoviral, and fibroviral hepatitis B who achieved remission with Lamivudine.

Authors:  Katsuhiko Matsumaru; Koji Ishii; Masao Shinohara; Yasukiyo Sumino; Atsushi Aikawa; Akira Hasegawa; Hiroko Nonaka; Michio Akima
Journal:  J Clin Gastroenterol       Date:  2003-02       Impact factor: 3.062

2.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 3.  Nonalcoholic steatohepatitis.

Authors:  A E Reid
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

Review 4.  Nonalcoholic steatohepatitis.

Authors:  S G Sheth; F D Gordon; S Chopra
Journal:  Ann Intern Med       Date:  1997-01-15       Impact factor: 25.391

5.  Host- and disease-specific factors affecting steatosis in chronic hepatitis C.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  J Hepatol       Date:  1998-08       Impact factor: 25.083

6.  Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.

Authors:  Johan Westin; Hans Nordlinder; Martin Lagging; Gunnar Norkrans; Rune Wejstål
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

7.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

8.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

9.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

Authors:  L Castéra; C Hézode; F Roudot-Thoraval; A Bastie; E-S Zafrani; J-M Pawlotsky; D Dhumeaux
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  19 in total

Review 1.  Nonalcoholic fatty liver disease and HIV infection.

Authors:  Raphael B Merriman
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

2.  Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B.

Authors:  Fehmi Ateş; Mehmet Yalnız; Saadet Alan
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

Review 3.  Steatosis as a co-factor in chronic liver diseases.

Authors:  Marcello Persico; Achille Iolascon
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

Review 4.  Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.

Authors:  Chu-wen Lin; Xiao-li Huang; Hai-lin Liu; Yan Wang
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

5.  Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.

Authors:  Rosa Zampino; Nicola Coppola; Grazia Cirillo; Adriana Boemio; Anna Grandone; Maria Stanzione; Nicolina Capoluongo; Aldo Marrone; Margherita Macera; Evangelista Sagnelli; Luigi Elio Adinolfi; Emanuele Miraglia del Giudice
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

6.  Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.

Authors:  Bulent Yilmaz; Seyfettin Koklu; Huseyin Buyukbayram; Kendal Yalçin; Ugur Korkmaz; Emrah Posul; Guray Can; Mevlut Kurt
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

7.  Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome.

Authors:  G Forlani; P Di Bonito; E Mannucci; B Capaldo; S Genovese; M Orrasch; L Scaldaferri; P Di Bartolo; P Melandri; A Dei Cas; I Zavaroni; G Marchesini
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

8.  Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.

Authors:  Yu-Qiang Mi; Qi-Yu Shi; Liang Xu; Rui-Fang Shi; Yong-Gang Liu; Ping Li; Feng Shen; Wei Lu; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-09-07       Impact factor: 3.199

9.  Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients.

Authors:  Yi-Cheng Chen; Chao-Wei Hsu; Wen-Juei Jeng; Chun-Yen Lin
Journal:  Dig Dis Sci       Date:  2021-02-10       Impact factor: 3.199

10.  Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis.

Authors:  Rui-dan Zheng; Jian-neng Chen; Qun-ying Zhuang; Yan-hui Lu; Jie Chen; Bi-fen Chen
Journal:  Int J Med Sci       Date:  2013-03-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.